Navamedic ASA Reports Double-Digit Growth in Q3 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, delivered revenues of NOK 138.9 million in Q3 2025, representing a 12.9% increase from Q3 2024.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024. Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
The revenue growth was driven by increases in all three business areas, including the Rx business area, which generated NOK 10.6 million in revenues from the dne business.
No direct quote available in the provided text.
For more information, contact +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT.
Author's summary: Navamedic ASA reports 12.9% revenue growth in Q3 2025.
More News
- WEED TAX NIXED: Humboldt County Supervisors Zero Out Measure S, Citing Industry Woes
- Elaine Hendrix on Vegan Living, ‘Dancing With the Stars’, and Life After ‘The Parent Trap’
- Chiodo and Keystone liquidators continue stoush over Shield remediation
- Copperopolis Man Arrested After Waving Around Switchblade - myMotherLode.com
- Bantam River Riders defeat Hague in first ever matchup of communities - Prince Albert Daily Herald
- 'DWTS': Alix Earle Slays Halloween Night With Monster Tango to Billie Eilish's 'Bury a Friend'
- Blimey! Green Party now polling in FIRST for all voters under 50
- Army Escalates Demolitions Across Occupied West Bank
- V1, ECH among proposed demolitions in new Campus Plan update